Skip to main content
Article thumbnail
Location of Repository

Genetically Engineered Mouse Models of Brain Cancer and the Promise of Preclinical Testing

By Jason T Huse and Eric C Holland

Abstract

Recent improvements in the understanding of brain tumor biology have opened the door to a number of rational therapeutic strategies targeting distinct oncogenic pathways. The successful translation of such “designer drugs” to clinical application depends heavily on effective and expeditious screening methods in relevant disease models. By recapitulating both the underlying genetics and the characteristic tumor-stroma microenvironment of brain cancer, genetically engineered mouse models (GEMMs) may offer distinct advantages over cell culture and xenograft systems in the preclinical testing of promising therapies. This review focuses on recently developed GEMMs for both glioma and medulloblastoma, and discusses their potential use in preclinical trials. Examples showcasing the use of GEMMs in the testing of molecularly targeted therapeutics are given, and relevant topics, such as stem cell biology, in vivo imaging technology and radiotherapy, are also addressed

Topics: Mini-Symposium: Mouse Models of Brain Tumors
Publisher: Blackwell Publishing Ltd
OAI identifier: oai:pubmedcentral.nih.gov:2659383
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2000). A
    2. (1998). A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice.
    3. (2006). A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway.
    4. (2007). A perivascular niche for brain tumor stem cells.
    5. (1994). Aggressive medulloblastoma with high-level N-myc amplification. Mayo Clin Proc 69:359–365.
    6. (1997). Altered neural cell fates and medulloblastoma in mouse patched mutants.
    7. (2005). An update on oligodendroglial neoplasms.
    8. (2004). Analysis of the activation status ofAkt, NFkB, and Stat3 in human diffuse gliomas. Lab Invest 84:941–951.
    9. Angenendt P et al (2008) An integrated genomic analysis of human glioblastoma multiforme.
    10. (2007). Apoptosis suppression by somatic cell transfer of Bcl-2 promotes Sonic hedgehog-dependent medulloblastoma formation in mice.
    11. (2002). Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation.
    12. (2001). Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas.
    13. (1998). Basic fibroblast growth factor induces cell migration and proliferation after glia-specific gene transfer in mice.
    14. Batish SD et al (2003) Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia.
    15. (2007). BRCA2 is required for neurogenesis and suppression of medulloblastoma.
    16. C et al (2006) XRCC4 suppresses medulloblastomas with recurrent translocations in p53-deficient mice.
    17. (2003). c-Myc enhances sonic hedgehog-induced medulloblastoma formation from nestin-expressing neural progenitors in mice.
    18. CairncrossJG,UekiK,ZlatescuMC,LisleDK,FinkelsteinDM,Silver RRHet al(1998)Specificgeneticpredictorsofchemotherapeutic responseandsurvivalinpatientswithanaplasticoligodendrogliomas.J NatlCancerInst90:1473–1479.
    19. (1996). CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
    20. (1996). Chidambaram A et al
    21. (2000). Combined activation of Ras andAkt in neural progenitors induces glioblastoma formation in mice.
    22. (2001). Concurrent inactivation of RB1 andTP53 pathways in anaplastic oligodendroglioma.
    23. Di Majo V et al (2006) Linking DNA damage to medulloblastoma tumorigenesis in patched heterozygous knockout mice.
    24. (1990). DIfferential expression of ros oncogene in primary human astrocytomas and astrocytoma cell lines.
    25. (2004). Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model.
    26. (2000). Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.
    27. (2002). DNA ligase IV suppresses medulloblastoma formation. Cancer Res 62:6395–6399.
    28. (2004). Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res 64:4783–4789.
    29. (2005). Essential role for Ras signaling in glioblastoma maintenance.
    30. (2000). Evidence that haploinsufficiency of Ptch leads to medulloblastoma in mice.
    31. (2006). Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res 66:3355–3359.
    32. (1990). Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.
    33. (2008). Giordano A
    34. (2008). Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas.
    35. (2005). Guha A
    36. Han YG et al (2008) Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma.
    37. Harada C et al (2005) Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.
    38. (2006). High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model.
    39. (2003). Indentification of a cancer stem cell in human brain tumors.
    40. (1998). Induction of brain tumors in mice using a recombinant platelet-derived growth factor b-chain retrovirus. Cancer Res 58:5275–5279.
    41. (2002). Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activatedAkt.
    42. Kuriyama H et al (2003) Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res 63:1589–1595.
    43. (2001). Loss of p53 but notARF accelerates medulloblastoma in mice heterozygous for patched.
    44. (2007). Loss of suppressor-of-fused function promotes tumorigenesis.
    45. Magdaleno S et al (2005) The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes Dev 19:2656–2667.
    46. Majo VD et al (2002) High incidence of medulloblastoma following X-ray-irradiation of newborn Ptc1 heterozygous mice.
    47. (2008). Malignant gliomas in adults.
    48. (2008). Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells.
    49. (2004). Medulloblastoma: signalling a change in treatment. Lancet Oncol 5:209–218.
    50. (1997). Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched.
    51. (1998). Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system.
    52. (1994). Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.
    53. (2005). Molecular genetics of tumors of the central nervous system.
    54. (2005). Molecular pathology of central nervous system tumors.
    55. (2009). Mouse Models and Preclinical Trials Huse &
    56. (2008). Mouse Models and Preclinical Trials Huse & Holland 140 Brain Pathology 19 (2009) 132–143 ©
    57. (2006). Mouse models of brain tumors and their application in preclinical trials.
    58. (2005). mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma.
    59. (2006). N-myc can substitute for insulin-like growth factor signaling in a mouse model of sonic hedgehog-induced medulloblastoma.
    60. (2003). N-myc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors.
    61. (2005). Natural history of neurofibromatosis 1-associated optic nerve glioma in mice.
    62. (2000). Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects.
    63. (2003). Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a ras transgenic mouse astrocytoma model.
    64. (1997). Pawson A
    65. (2001). PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo.
    66. (2005). Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.
    67. (1998). Platelet-derived growth factor and its receptor expression in human oligodendrogliomas.
    68. (1995). Platelet-derived growth factor in human glioma.
    69. (2008). Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma.
    70. (2002). Prediction of central nervous system embryonal tumour outcome based on gene expression.
    71. (2008). Pten haploinsufficiency accelerates formation of high-grade astrocytomas.
    72. (2008). Rethinking brain tumors: the fourth mouse models of human cancers consortium nervous system tumors workshop.
    73. (2006). ROS fusion tyrosine kinase activates a SH2 domain-containing phospatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice.
    74. RP et al (2005) Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma.
    75. (2006). Shh pathway activity is down-regulated in cultured medulloblastoma cells: implications for preclinical studies.
    76. (2005). Somatic induction of pten loss in a preclinical astrocytoma model reveals major roles in disease progression and avenues for target discovery and validation.
    77. (2004). Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice.
    78. (1997). Sporadic medulloblastomas contain PTCH mutations.
    79. Stegh A et al (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21:2683–2710.
    80. (1992). Structural alterations of the epidermal growth factor receptor gene in human gliomas.
    81. (2004). Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice.
    82. Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
    83. (2008). The Cancer GenomeAtlas Research Network
    84. (2006). The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 5:741–754.
    85. (2000). The normal patched allele is expressed in medulloblastomas from mice with heterozygous germ-line mutation of patched.
    86. (2008). The origins of medulloblastoma subtypes. Annu Rev Pathol 3:341–365.
    87. (1994). The p53 gene and protein in human brain tumors.
    88. (1994). The retinoblastoma gene is involved in the malignant progression of astrocytomas.
    89. (2008). The Smo/Smo model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread.
    90. (2004). The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas.
    91. (2008). Transient inhibition of the Hedgehog pathway in young mice causes permanent defects in bone structure.
    92. (2009). Tumor Mouse Models and Preclinical Trials 141
    93. (2009). Tumor Mouse Models and Preclinical Trials 143
    94. Wu TD et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.